Logo.png
Bladder Cancer Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 70+ Companies Working in the Domain
14 mai 2024 13h00 HE | DelveInsight Business Research LLP
New York, USA, May 14, 2024 (GLOBE NEWSWIRE) -- Bladder Cancer Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 70+ Companies Working in the Domain ...
cgoncology_cover.jpg
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
09 mai 2024 08h00 HE | CG Oncology Inc.
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
cgoncology_cover.jpg
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
03 mai 2024 11h23 HE | CG Oncology Inc.
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
biodexa-logo-square (1).png
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)
26 avr. 2024 08h30 HE | Biodexa Pharmaceuticals PLC
April 26, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for theTreatment of Familial Adenomatous Polyposis (FAP)...
cgoncology_cover.jpg
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
26 avr. 2024 08h00 HE | CG Oncology Inc.
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
cgoncology_cover.jpg
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
24 avr. 2024 10h00 HE | CG Oncology Inc.
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
LUDG.png
Ludwig Enterprises Inc (OTC:LUDG) Enters Booming Artificial Intelligence Cancer Screening Market with its Non-Invasive Cancer Diagnostics Testing Kit, launching within 2024
19 mars 2024 08h00 HE | Ludwig Enterprises, Inc.
SPARKS, Nev., March 19, 2024 (GLOBE NEWSWIRE) -- Ludwig Enterprises, Inc, (OTC: LUDG): A US-based biotechnology company is pleased to announce it has entered the booming artificial intelligence...
LUDG.png
Ludwig Enterprises Inc. (OTC:LUDG) Announces Patent Filing for Breakthrough in Identifying mRNA Genes Associated with Certain Cancers
06 mars 2024 08h00 HE | Ludwig Enterprises, Inc.
Ludwig Enterprises, Inc. (OTC: LUDG): A US-based biotechnology company is pleased to announce the successful filing of its provisional patent
22157.jpg
Non-muscle Invasive Bladder Cancer (NMIBC) Epidemiology Forecasts to 2034
25 janv. 2024 09h04 HE | Research and Markets
Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Non-muscle Invasive Bladder Cancer (NMIBC) - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. The...
22157.jpg
Oncology Nutrition Market Experiences Growth with Rise in Personalized and Immuno-nutrition Trends
22 janv. 2024 21h28 HE | Research and Markets
Dublin, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The "Oncology Nutrition Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The recent comprehensive analysis within...